Clinical Significance of PLA2G2A Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1

被引：12

作者：

Hatori, Shinsuke ^{[1
,2
]}

Sakamaki, Kentaro ^{[3
]}

Yokohori, Takehiko ^{[4
]}

Kimura, Yayoi ^{[5
]}

Hiroshima, Yukihiko ^{[6
]}

Hashimoto, Itaru ^{[1
]}

Komori, Keisuke ^{[1
]}

Watanabe, Hayato ^{[1
]}

Kano, Kazuki ^{[1
]}

Fujikawa, Hirohito ^{[1
]}

Aoyama, Toru ^{[2
]}

Numata, Masakatsu ^{[2
]}

Yamada, Takanobu ^{[1
]}

Tamagawa, Hiroshi ^{[2
]}

Yamamoto, Naoto ^{[1
]}

Ogata, Takashi ^{[1
]}

Shizawa, Manabu ^{[1
]}

Yukawa, Norio ^{[2
]}

Morinaga, Soichiro ^{[2
]}

Rino, Yasushi ^{[2
]}

Masuda, Munetaka ^{[2
]}

Saeki, Hiroshi ^{[4
]}

Miyagi, Yohei ^{[6
]}

Oshima, Takashi ^{[1
]}

机构：

[1] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, 2-3-2 Nakano Asahi, Yokohama, Kanagawa 2418515, Japan

[2] Yokohama City Univ, Dept Surg, Yokohama, Kanagawa, Japan

[3] Yokohama City Univ, Dept Data Sci, Yokohama, Kanagawa, Japan

[4] Gunma Univ, Dept Gastroenterol Surg, Maebashi, Gumma, Japan

[5] Yokohama City Univ, Advanced Med Res Ctr, Yokohama, Kanagawa, Japan

[6] Kanagawa Canc Ctr Res Inst, Yokohama, Kanagawa, Japan

来源：

ANTICANCER RESEARCH | 2021年 / 41卷 / 07期

关键词：

Gastric cancer; S-1; prognostic factor; PLA2G2A; GROUP IIA PHOSPHOLIPASE-A2; OPEN-LABEL; STAGE-II; CHEMOTHERAPY; CAPECITABINE; OXALIPLATIN; SURVIVAL;

D O I：

10.21873/anticanres.15146

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: This study aimed to evaluate the prognostic significance of PLA2G2A expression in patients with locally advanced gastric cancer (GC). Patients and Methods: PLA2G2A expression levels in cancerous tissue specimens and adjacent normal mucosa obtained from 134 patients with stage II/III GC who received adjuvant chemotherapy with S-1 after curative resection were measured using real-time quantitative polymerase chain reaction. Subsequently, the associations of PLA2G2A expression with clinicopathological features and survival were evaluated. Results: No association was observed between clinicopathological features and PLA2G2A expression levels. Overall survival was significantly longer in patients with high PLA2G2A expression levels (p=0.022). Multivariate analysis revealed that PLA2G2A expression was a significant, independent prognostic factor (hazard ratio=0.136; 95% confidence interval=0.0185-0.992; p=0.049). Conclusion: PLA2G2A mRNA expression may serve as a useful prognostic marker in patients with locally advanced GC who receive curative surgery and adjuvant chemotherapy with S-1.

引用

页码：3583 / 3588

页数：6

共 50 条

[21] Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1
Aoyama, Toru
Yoshikawa, Takaki
Watanabe, Takafumi
Hayashi, Tsutomu
Ogata, Takashi
Cho, Haruhiko
Tsuburaya, Akira
GASTRIC CANCER, 2011, 14 (03) : 274 - 278
[22] Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1
Toru Aoyama
Takaki Yoshikawa
Takafumi Watanabe
Tsutomu Hayashi
Takashi Ogata
Haruhiko Cho
Akira Tsuburaya
Gastric Cancer, 2011, 14 : 274 - 278
[23] Clinical Significance of Glioma-associated Oncogene 1 Expression in Patients With Locally Advanced Gastric Cancer Administered Adjuvant Chemotherapy With S-1 After Curative Surgery
Hashimoto, Itaru
Oue, Naohide
Kimura, Yayoi
Hiroshima, Yukihiko
Hara, Kentaro
Maezawa, Yukio
Kano, Kazuki
Fujikawa, Hirohito
Aoyama, Toru
Numata, Masakatsu
Yamada, Takanobu
Tamagawa, Hiroshi
Yamamoto, Naoto
Ogata, Takashi
Shiozawa, Manabu
Morinaga, Soichiro
Rino, Yasushi
Yasui, Wataru
Masuda, Munetaka
Miyagi, Yohei
Oshima, Takashi
ANTICANCER RESEARCH, 2020, 40 (10) : 5815 - 5821
[24] Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy
Shitara, Kohei
Chin, Keisho
Yoshikawa, Takaki
Katai, Hitoshi
Terashima, Masanori
Ito, Seiji
Hirao, Motohiro
Yoshida, Kazuhiro
Oki, Eiji
Sasako, Mitsuru
Emi, Yasunori
Tsujinaka, Toshimasa
GASTRIC CANCER, 2017, 20 (01) : 175 - 181
[25] Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy
Kohei Shitara
Keisho Chin
Takaki Yoshikawa
Hitoshi Katai
Masanori Terashima
Seiji Ito
Motohiro Hirao
Kazuhiro Yoshida
Eiji Oki
Mitsuru Sasako
Yasunori Emi
Toshimasa Tsujinaka
Gastric Cancer, 2017, 20 : 175 - 181
[26] Clinical significance of S100A2 expression in gastric cancer
Liu, Ying-Fu
Liu, Qing-Qing
Wang, Xuan
Luo, Chun-Hua
TUMOR BIOLOGY, 2014, 35 (04) : 3731 - 3741
[27] Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapy
Murakawa, Masaaki
Aoyama, Toru
Miyagi, Yohei
Atsumi, Yosuke
Kazama, Keisuke
Yamaoku, Koichiro
Kanazawa, Amane
Shiozawa, Manabu
Kobayashi, Satoshi
Ueno, Makoto
Morimoto, Manabu
Yamamoto, Naoto
Oshima, Takashi
Yoshikawa, Takaki
Rino, Yasushi
Masuda, Munetaka
Morinaga, Soichiro
ONCOLOGY LETTERS, 2017, 14 (02) : 1505 - 1511
[28] Retrospective study of the patients with unresectable gastric cancer (UNGC) who underwent a gastrectomy after receiving S-1 or S-1 combination chemotherapy (S-1+α)
Kobayashi, K.
Tsuji, A.
Hata, Y.
Morita, S.
Horimi, T.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[29] A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer
Li, Ning
Wu, Hui
Xu, Xin
Wei, Qinming
Ding, Yongfeng
Liu, Shan
Wu, Jinqiong
Zheng, Yulong
Xu, Nong
Gao, Yuan
Jiang, Haiping
SCIENTIFIC REPORTS, 2024, 14 (01):
[30] Prognostic significance of CKS2 and CD47 expression in patients with gastric cancer who underwent radical gastrectomy
Zhou, Yang
Zeng, Jing
Zhou, Wei
Wu, Keyan
Tian, Zhen
Shen, Weigan
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2022, 96 (04)

← 1 2 3 4 5 →